OptiBiotix Health PLC SlimBiome launch to EU market at Vitafoods Europe
01 Mayo 2019 - 1:01AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
01 May 2019
OptiBiotix Health Plc
("OptiBiotix")
OptiBiotix to launch SlimBiome(R) Medical to the EU market at
Vitafoods Europe 2019
OptiBiotix Health Plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol and
diabetes, is to commercially launch its innovative weight
management solution SlimBiome(R) Medical ('SlimBiome(R)') to the
European market on May 7, at Vitafoods Europe 2019.
SlimBiome(R), which is a CE marked medical device, offers a
healthy, hunger-free weight management solution designed for use by
itself, or as part of a calorie-restricted diet, to reduce hunger
and help users achieve sustainable weight loss. Independent
clinical studies show SlimBiome(R) reduces hunger, cravings for
sweet and savoury foods, and fat intake.
Taking place from May 7 until May 9, Vitafoods Europe 2019
brings together nutraceutical expertise from more than 110
countries. This year's event will be held in Geneva, Switzerland
and OptiBiotix will be exhibiting alongside Nutrilinea on stand
B20.
This commercial launch follows on from the announcement that
SlimBiome(R) was granted medical device status and a CE mark in
November 2018 (RNS: 27 November 2018), followed by the appointment
of Nutrilinea S.R.L as a manufacturer (RNS: 29 November 2018) and
the signature of distribution agreements for Greece, Cyprus (RNS: 4
December 2018) and Bulgaria (RNS: 9 April 2019) as well as the
successful commercial launch to the UK market on April 29 2019
(RNS: 24 April 2019).
Fred Narbel, Managing Director of the Prebiotics division,
commented: "We are delighted to present SlimBiome(R) Medical to the
EU market at Vitafoods as it is one of the most significant annual
nutraceutical events in Europe. The launch allows us to continue to
deliver on our sales strategy of building multiple revenue streams
across various sales channels because it will help us accelerate
the expansion our distribution and sales network in Europe and
beyond and support recent distribution agreements we have
established."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAMMGFDFGFGLZM
(END) Dow Jones Newswires
May 01, 2019 02:01 ET (06:01 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024